In a recent study, cfDNA was shown to be as reliable as NSE and LDH in discriminating NB patients with newly diagnosed (n = 79) versus stable (n = 79) disease (area under the curve (AUC), 0.953, 0.929 and 0.906, respectively). This evidence concerns the gene ENO2 and neuroblastoma.